5 of Last Week's Biggest Winners

What's better than momentum? Mo' momentum. Let's take a closer look at five of this past week's biggest scorchers.

Company

Jan. 10

Weekly Gain

Intrexon  (NYSE: XON  )

$29.87

27%

TASER International  (NASDAQ: TASR  )

$18.68

19%

BlackBerry  (NASDAQ: BBRY  )

$8.76

15%

LightInTheBox  (NYSE: LITB  )

$9.13

12%

MannKind (NASDAQ: MNKD  )

$5.92

10%

Source: Barron's.

Let's start with Intrexon. The provider of synthetic biology solutions moved higher after announcing that its CEO will present at the J.P. Morgan Healthcare Conference. The presentation will be on Wednesday afternoon, giving the company the opportunity to educate the market on its UltraVector platform that facilitates the design and development of complex biological systems.

TASER moved higher after announcing a flurry of contracts to close out 2013. The stun-gun maker issued a press release detailing more than a dozen weapon deployments and more than two dozen organizations deploying TASER SMART weaponry.

BlackBerry closed higher every single trading day last week. The week kicked off with another executive hire, bringing in someone to run its devices division. BlackBerry then generated some buzz during the CES exposition by talking up smartphones with physical keyboards, like when the company was in its prime.

LightInTheBox moved higher after acquiring a social e-commerce company. LightInTheBox's all-cash deal for Seattle-based Ador gives it a physical stateside presence for the first time. LightInTheBox is based in China, where it sources formalwear and housewares that it sells overseas. Europe currently represents its biggest market. It remains to be seen whether Ador can move the needle for a company that has posted disappointing financials since going public last year, but investors seem to be excited about the push to shake things up by going shopping.

MannKind was on a roller-coaster ride, soaring on Thursday and tumbling on Friday. The Endocrinologic and Metabolic Drugs Advisory Committee is tentatively looking at April for a review of Afrezza, MannKind's potentially game-changing inhalable insulin treatment. If this past week's volatility was wild, one can only imagine the wild swings that wait in April based on the results of the review.

Keep the good vibes coming
As every savvy investor knows, Warren Buffett didn't make billions by betting on half-baked stocks. He isolated his best few ideas, bet big, and rode them to riches, hardly ever selling. You deserve the same. That's why our CEO, legendary investor Tom Gardner, has permitted us to reveal The Motley Fool's 3 Stocks to Own Forever. These picks are free today! Just click here now to uncover the three companies we love. 


Read/Post Comments (1) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On January 12, 2014, at 9:41 AM, WCoastGuynCA wrote:

    Mannkind has acknowledged that the use of Afrezza causes diminished lung capacity but that the lungs return to "normal" after the patients stopped using Afrezza.

    The question is whether or not this is acceptable to the F.D.A. Also the long term effects will have to be closely scrutinized.

    Both of these issues are probably connected to Mannkind's failure to find a "big pharma" marketing partner to date.

    How ironic is it that the committee is meeting on April Fool's Day.

Add your comment.

DocumentId: 2792018, ~/Articles/ArticleHandler.aspx, 4/24/2014 11:11:59 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement